Posts Tagged ‘multiple sclerosis’

Categories

Posted in:

Wednesday January 04th, 2017

A new drug has been developed for the treatment of autoimmune diseases

IDIBAPS researchers have participated in a study that shows how a new experimental drug could curb a wide variety of autoimmune diseases such as asthma, psoriasis, Crohn’s disease or multiple sclerosis without blocking the body’s natural response against infections caused by pathogens.

Read the rest of this entry »

Comments Closed
Monday July 27th, 2015

Begins a clinical trial of a new technique to treat Multiple Sclerosis and Neuromyelitis Optica

The Spanish Agency for Medicines and Health Products (AEMPS) has approved a clinical trial in humans with an Antigen-Specific therapy with dendritic cells, a pioneering technique for the treatment of Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) in a more effective way and with fewer side effects. Dr. Pablo Villoslada, head of the IDIBAPS group Pathogenesis and new treatments in multiple sclerosis, and Dr. Daniel Benitez, researcher at the Inflammatory bowel disease IDIBAPS team, coordinate this trial led by the Hospital Clinic and driven by the Multiple Sclerosis Affected Group Foundation (GAEM) and “la Caixa” Foundation.

Read the rest of this entry »

Comments Closed
Friday July 03rd, 2015

Researchers from IDIBAPS and Hospital Clínic create the first application containing all the available knowledge on Multiple Sclerosis

Researchers from IDIBAPS and Hospital Clinic of Barcelona have created the first ontology that contains knowledge about Multiple Sclerosis (MS) to advance in translational and clinical research about this disease. This tool allows gathering useful information about the treatments or diseases associated with MS which can be found both in scientific articles and medical records. In the study, coordinated by Dr. Pablo Villoslada, head of the IDIBAPS group Pathogenesis and new treatments in multiple sclerosis, Dr. Xavier Pastor and Dr. Raimundo Lozano form the Medical Informatics Unit of Hospital Clinic, and Dr. Albert Saiz, from the Neurology Department at the hospital, have participated.

Read the rest of this entry »

Comments Closed
Wednesday December 04th, 2013

The study of the retina offers a noninvasive way to visualize the evolution of multiple sclerosis

Neurodegenerative diseases are chronic and still lacking an effective treatment, so they have become a growing concern in our aging society. The lack of therapies adds to the difficulty of studying the effect of new drugs on the brain, because it is not possible to perform a complete diagnosis and pathological study before the death of the patient. The Annals of Neurology published a paper showing that it is possible to monitor the evolution of MS through the retina. Dr. íñigo Gabilondo is the first author of the work, while the last one is Dr. Pablo Villoslada, head of Multiple Sclerosis, Pathogenesis and New Therapies Group at the IDIBAPS’ Neuroimmunology Program. The work was done in collaboration with the Department of Neurology and Ophthalmology at Hospital Clinic of Barcelona, which form the Visual Pathway Laboratory, funded by the Instituto de Salud Carlos III.

Read the rest of this entry »

Comments Closed
Monday November 04th, 2013

Bionure and Myelin Repair Foundation will collaborate to advance a therapy for multiple sclerosis

The Myelin Repair Foundation and Bionure have entered a collaborative partnership agreement to advance therapeutics development for Multiple Sclerosis. In this agreement, the Myelin Repair Foundation will work closely with Bionure, Inc. to assess the neuroprotective capabilities that will promote myelin repair of the company’s proprietary MS therapeutic compound, BN201. The main objective is to advance promising compounds into the clinic. Bionure is a Silicon Valley and Barcelona based early stage drug development company focused on developing neuroprotective therapies for the treatment of neurodegenerative diseases. It is a Spin-Off company based on a Hospital Clínic – IDIBAPS – CSIC research, which was started by Dr. Pablo Villoslada, investigator at the IDIBAPS team Clinical and experimental neuroimmunology.

Read the rest of this entry »

Comments Closed
Friday December 23rd, 2011

A very rigorous management of peripheral infections may be beneficial in Multiple Sclerosis

The team on MS led by Dr. Pablo Villoslada. Source: Diario Médico
Infections trigger the immune system, responsible for fighting them. On the other hand, there is evidence that the innate immune system is involved in the onset of neurological lesions typical of multiple sclerosis (MS). That is why researchers at the Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), along with researchers at the University of Southampton (Kingdom Clinical Neuroscience Unit and CNS Inflammation group), investigated if peripheral infections could worsen the prognosis of this disease in an experimental model with rats. The first author of the study published in Annals of Neurology is Dr. Beatriz Moreno, from the IDIBAPS’ group Pathogenetics and new therapies in MS.

Read the rest of this entry »

Comments Closed
Page 1 of 212